Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Important Ordering Details

Custom Ordering Details: This product is assembled upon order. Please allow up to three weeks for your product to be processed

Pricing & Additional Information

To learn more about our Blocking Peptides, including pricing, please answer a few questions.

Pricing & Additional Information  

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Immunohistochemical analysis of paraffin-embedded human renal adenocarcinoma, using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb (#2243) in the presence of contol peptide (left) or Phospho-HER2/ErbB2 (Tyr1221/1222) Blocking Peptide (right).

Learn more about how we get our images
Image

Product Description

This peptide is used to block Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb #2243 reactivity.


Quality Control

The quality of the peptide was evaluated by reverse-phase HPLC and by mass spectrometry. The peptide blocks Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb # 2243 signal in immunohistochemistry.

Product Usage Information

Use as a blocking reagent to evaluate the specificity of antibody reactivity in immunohistochemistry protocols. For Immunohistochemistry, add twice the volume of peptide as volume of antibody used in a 100 ul total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the Phospho HER2/ErbB2 (Tyr 1221/1222)(6B12) Rabbit mAb #2243 data sheet.


Storage: Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. Store at –20°C.

The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).


1.  Muthuswamy, S.K. et al. (1999) Mol Cell Biol 19, 6845-57.

2.  Qian, X. et al. (1994) Proc Natl Acad Sci USA 91, 1500-4.

3.  Dittadi, R. and Gion, M. (2000) J Natl Cancer Inst 92, 1443-4.

4.  Klapper, L.N. et al. (2000) Cancer Res 60, 3384-8.

5.  Kwon, Y.K. et al. (1997) J Neurosci 17, 8293-9.


Entrez-Gene Id 2064
Swiss-Prot Acc. P04626


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.